Cipla Slashes Rates of Cancer Medications In Indian Market

Cipla Slashes Rates of Cancer Medications In Indian MarketCipla Ltd. has slashed the rates of a few of the generic medications, which it sells in the Indian market for the treatment of cancers of the lung, liver, kidney and the brain by around 75%.

The pharma giant stated that it will now market sorafenib, the generic edition of Bayer AG's kidney- and liver-cancer medication Nexavar, for Rs 6,840 rupees for a month's therapy as against Rs 28,000 earlier.

The company has cut the cost of a pack of five capsules of brain-cancer medicine temozolamide in 250-milligram doses to Rs 5,000 as against Rs 20,250.

A bundle of 30 pills of 250-mg dose lung-cancer medicine gefitinib will be available at a price of Rs 4,250 as against Rs 10,200 previously.

AstraZeneca PLC, the leader of the lung-cancer medication, markets it under the trade name Iressa.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate